Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis.
Clinical Brief: Emerging Therapies for Bronchiectasis
Main Discussion Topics
Key Points for Physicians
Notable Insights
Peripheral eosinophil counts may help guide treatment decisions similar to their use in chronic obstructive pulmonary disease management, with different thresholds being investigated.
Clinical Significance
Emerging therapies targeting specific inflammatory pathways show promise for more precise treatment of bronchiectasis based on inflammatory phenotype.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More